Navigation Links
Pharma Clinical Trial Services: World Market 2013-2023
Date:3/4/2013

NEW YORK, March 4, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Pharma Clinical Trial Services: World Market 2013-2023

http://www.reportlinker.com/p0595031/Pharma-Clinical-Trial-Services-World-Market-2013-2023.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Discovery_and_Development

Report Details

Discover new trends, opportunities and prospects for contract clinical trials What's the outlook for clinical research providers? Visiongain's updated report gives you forecasted revenues to 2023. It explains trends, opportunities and commercial prospects.

Our study lets you assess sales data at overall world market, submarket and national level. There you find the most promising and lucrative areas in clinical trial outsourcing, helping your research and analyses.

Forecasts and other analyses to help you stay ahead in knowledge

In our work you find revenue forecasting to 2023, historical data, growth rates and market shares. Also, you see qualitative analysis (SWOT and STEP), business news, outlooks and developmental trends (R&D). You receive 74 tables, 61 charts and two survey interviews.

There's rising demand for that pharma research. The outsourced clinical trials market will increase its revenues from 2013 to 2023, achieving strong growth. Clinical research organisations (CROs) and their clients will benefit.

The following sections show what you find in our new report.

Discover prospects for the world market and submarkets

Along with revenue prediction for the overall world market, you see forecasts to 2023 for eight submarkets:• Early phase clinical trial services• Late phase services.

We also show forecasts for contract services by therapeutic area:

• Cancers

• Central nervous system (CNS) diseases

• Cardiovascular diseases

• Infections

• Metabolic disorders

• Other therapy areas (grouped prediction).

You gain advantages by understanding trends, opportunities and challenges. Our investigation shows what will stimulate and restrain business for CROs.

Our work also breaks the main world forecast into geographical markets.

What prospects for leading regions and countries? Developments worldwide will influence the market from 2013, especially improving clinical research in developing countries. There exist many opportunities for pharmaceutical companies and contract research providers. See outlooks for clinical testing.

You get individual forecasts to 2023 for 12 national markets and two regional groups, finding overall revenues:• US• Japan• Western Europe• Central and Eastern Europe (CEE)• Germany, France, UK, Italy and Spain (EU5)• Brazil, Russia, India and China (BRIC nations) and South Korea.

Discover progress and outlooks. You assess the industry's future - hear about developments and find their significance. Our work explains, exploring many issues.

What affects clinical trial services from 2013? Our report discusses issues and events affecting that industry and market from 2013:

• Future of outsourced phase I, II and III trials and post-marketing studies

• Demand from pharmaceutical and biopharma companies

• Regulatory policy

• Challenges in developed and developing countries

• Adaptive trial designs and focus on late-stage R&D pipeline candidates

• Patient recruitment and retention.

Also, we discuss these aspects of the field:• Social media as tools for engaging patients• Technological progress for more-efficient trials• Sharing of risk between the pharma industry and CROs• CRO consolidation, specialisation and globalisation• Studies on orphan diseases• Biomarkers in drug development.

See what the future holds. You investigate technological, economic and political matters, finding emphasis on companies, competition and business outlooks.

Leading companies and 2015 market value We predict that the overall world market for clinical trial services will reach $30.6bn in 2015, and expand further to 2023. That outsourcing segment holds great potential for investment, development and revenue growth from 2013. You see how it will progress.

We review 15 leading companies, including these:• Quintiles• Covance• PPD• Parexel International• ICON• INC Research• inVentiv Health.

From 2013 to 2023, many opportunities will arise. Our work shows you the technological and commercial possibilities.

Eight ways Pharma Clinical Trial Services: World Market 2013-2023 helps To sum up, our investigation gives you the following knowledge:

• Revenues to 2023 for the overall world market and 8 submarkets - you discover the industry's prospects

• Market forecasting to 2023 for US, Japan, Germany, France, UK, Spain, Italy, South Korea, Brazil, Russia, India and China - you see national sales predictions

• Investigation of clinical trial services - out-contracting and off-shoring - you assess outlooks for pharma CROs and their clients

• Profiles of 15 leading companies - you hear about activities, recent results, strategies and outlooks for top service providers

• Opinions on the sector - you read our interviews with authorities in the industry

• Competition and opportunities influencing sales - you see what affects the future

• Discussions of what stimulates and restrains the industry and market - you explore business trends, drivers and restraints

• Prospects for established firms and those seeking to enter the sector - you assess needs, practices and outlooks for success.

You gain information found nowhere else That work gives independent analysis. You receive business intelligence found only in our report, seeing where technological and financial prospects are good.

With our study you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses and decisions, saving time and getting you recognition for insight.

Ordering now lets you discover commercial predictions to 2023

Visiongain's investigation is for everyone needing analysis of the clinical trials industry and market. You find data, trends and predictions. Please order our report now.

Visiongain is a trading partner with the US Federal Government

CCR Ref number: KD4R6

Table of Contents 1. Executive Summary 1.1 Pharma Clinical Trial Services: World Market Review

1.2 Report Contents

1.3 Research and Analysis Methods

2. An Introduction to Clinical Trial Outsourcing

2.1 A Brief History of Clinical Trials2.2 Clinical Trial Design and Execution2.2.1 Phases of Clinical Trials2.2.1.1 Phase I Trials: First-in-Human Studies2.2.1.2 Phase II Trials: Proof-of-Concept2.2.1.3 Phase III Trials: Preparing for Approval Applications2.2.1.4 Post-Marketing Studies2.2.2 Key Elements of Clinical Trials2.2.3 Common Trial Designs2.2.3.1 Improving Clinical Trial Models Through Adaptive Trial Designs2.3 Clinical Trial Outsourcing2.3.1 Challenges Exist in Conducting Clinical Trials2.3.2 Benefits of Outsourcing

3. The World Pharma Clinical Trial Services Market 2013-2023

3.1 The Pharma Clinical Trial Services Market 2011-2012

3.1.1 Rapid Growth in the Clinical Trial Outsourcing Market 2008-2011

3.1.2 CRO Revenue by Trial Phase 2011

3.1.3 Big Pharma Companies Are the Leading Clients for CROs

3.2 The Pharma Clinical Trial Services Market 2013-2023

3.2.1 What Will Drive Growth in Clinical Trial Outsourcing 2013-2023?

3.2.2 The Pharma Clinical Trial Services Market: Overall Revenue Forecast 2013-2023

3.2.3 Which Market Sector Will Account for Most Revenue 2013-2023?

3.3 Early Phase Clinical Trial Services 2013-2023

3.3.1 Rising Demand for Early Phase Services Throughout the Decade

3.3.2 Biotech Outsourcing to Drive Early Phase Growth

3.4 Late Phase Clinical Trial Services 2013-2023

3.4.1 Late Phase Clinical Trial Services: The Largest Market Sector 2013-2023

3.4.2 Focus on Last-Stage Pipeline Candidates Early in the Decade

4. Pharma Clinical Trial Services: Leading Developed Markets 2013-2023

4.1 Leading National Markets for Pharma Clinical Trial Services 20114.2 Pharma Clinical Trial Services: Leading National Market Forecasts 2013-20234.3 North America as a Destination for Clinical Trials4.3.1 The US: The Largest National Market for Clinical Trial Services 2013-20234.3.1.1 Regulatory Developments to Improve Clinical Trials in the US4.3.2 The US: Clinical Trial Service Revenue Forecast 2013-20234.4 The Outlook for Clinical Trial Services in Western Europe 2013-20234.4.1 Rewriting the Rules for Clinical Trials in the EU4.4.2 Western Europe: Overall Market and Leading National Market Forecasts 2013-20234.4.3 Germany Is the Largest Market for Clinical Trial Services in Western Europe4.4.4 France: Market Forecast 2013-20234.4.5 The UK4.4.5.1 Overcoming Challenges in UK Clinical Trials4.4.5.2 UK Clinical Trial Services Market Forecast 2013-20234.4.6 Italy4.4.7 Spain: Market Forecast 2013-20234.5 Japan Is Being Challenged by Neighbouring Emerging Markets4.5.1 Regulatory Policies Driving and Restraining Growth in Japan4.5.2 Growth for Clinical Trial Services in Japan 2013-2023

5. Pharma Clinical Trial Services: Leading Emerging Markets 2013-2023

5.1 Leading Emerging Markets for Clinical Trial Services 2011

5.1.1 Benefits of Conducting Clinical Trials in Emerging National Markets

5.1.2 Challenges of Conducting Clinical Trials in Emerging Markets

5.2 Strong Growth Forecast for Emerging Clinical Trial Service Markets 2013-2023

5.3 Clinical Trials in Asia Pacific: An Emerging Market Perspective

5.3.1 India as a Hub for Clinical Trials

5.3.1.1 Increasingly Strict Regulatory Procedures in India

5.3.1.2 Indian Clinical Trial Services Market Forecast 2013-2023

5.3.2 China Will be the Largest Emerging Market for Clinical Trials Services in 2023

5.3.2.1 China Offers Many Advantages in Clinical Trials

5.3.2.2 New Guidelines for Phase I Trials

5.3.3 South Korea

5.3.3.1 Improving the Appeal of South Korea

5.3.3.2 Promoting Local Drug Development in South Korea

5.3.3.3 Growth in the South Korean Clinical Trials Services Market 2013-2023

5.4 Clinical Trial Outsourcing in Central and Eastern Europe (CEE)

5.4.1 Russia

5.4.1.1 Changing Clinical Trial Demands 2010-2012

5.4.1.2 Russian Clinical Trial Services Market Forecast 2013-2023

5.4.2 CEE: Clinical Trial Services Market Forecast 2013-2023

5.5 Latin America: Proximity to the US as a Growth Driver

5.5.1 Brazil: The Largest Market for Clinical Trials in Latin America 2013-2023

5.5.1.1 Brazilian Clinical Trial Services Market Forecast 2013-2023

6. Leading Disease Market Sectors for Clinical Trial Services 2013-2023

6.1 The Pharma Clinical Trial Services Market by Therapeutic Area 2011-20126.2 The Pharma Clinical Trial Services Market: Revenue Forecast by Therapeutic Area 2013-20236.3 Imaging for CNS and Cardiovascular Clinical Trials6.4 Cancer Clinical Trials: Key Trends and Submarket Forecast 2013-20236.4.1 Biomarkers and Companion Diagnostic Development6.4.2 Optimising Patient Recruitment and Retention6.4.3 Many Factors Complicate Cancer Clinical Trials6.4.4 The Largest Submarket for Clinical Trial Services 2013-2023?6.5 CNS Clinical Trials: Key Trends and Submarket Forecast 2013-20236.5.1 Concerns with Placebo Response Rates in CNS Clinical Trials6.5.1.1 Cogtest: Data Capture and Cognitive Assessment6.5.2 Effective Use of Adaptive Trial Designs6.5.3 CNS Clinical Trials: Submarket Forecast 2013-20236.6 Cardiovascular Disease Clinical Trials: Key Trends and Submarket Forecast 2013-20236.6.1 Strong Growth in the Cardiovascular Disease Clinical Trial Services Submarket 2013-20236.7 Infectious Disease Clinical Trials: Key Trends and Submarket Forecast 2013-20236.7.1 Challenges in the Use of Non-Inferiority Trials6.7.2 Considerations for Antibacterial Drug Clinical Trials6.7.3 Vaccine Clinical Trials and Emerging Markets6.7.4 Infectious Disease Clinical Trial Services Submarket Forecast 2013-20236.8 Metabolic Disease Clinical Trials: Key Trends and Submarket Forecast 2013-20236.8.1 Assessing Cardiovascular Risks in Diabetes6.8.2 Metabolic Disease Clinical Trial Services Submarket Forecast 2013-20236.9 Therapeutic Expertise Provides an Opportunity for Specialisation6.9.1 CROs Offering Imaging Services

7. Pharma Clinical Trial Services Market: Industry Trends 2013-2023

7.1 Pharma Clinical Trial Services Market: Strengths and Weaknesses 2012

7.2 Pharma Clinical Trial Services Market: Opportunities and Threats 2013-2023

7.2.1 CRO Expertise in Biosimilars as an Opportunity

7.3 Pharma Clinical Trial Services Market: STEP Analysis 2013-2023

7.4 Social Factors Affecting Clinical Trials 2013-2023

7.4.1 Drug Developers Must Deal with Ethical Considerations to Clinical Trials

7.4.2 Patient Recruitment: The Leading Cause of Trial Delays

7.4.3 Investing to Maintain Patient Enrolment

7.4.3.1 Social Media as a Tool for Engaging Patients in Trials

7.5 Improving Technology for More-Efficient Trials

7.5.1 eClinical Trial Tools

7.5.1.1 Electronic Health Records for Faster Patient Recruitment

7.5.2 Cloud Computing as a Tool for Multicentre Trials

7.5.3 Electronic Data Capture

7.6 Economic Considerations for Clinical Trial Outsourcing

7.6.1 Pharma is Adjusting its R&D Strategies

7.6.2 CROs are Attractive for Private Investors

7.7 Political and Regulatory Developments Affecting Clinical Trials

7.7.1 Drug Safety and Clinical Trials Post-Approval

7.7.2 Cutting Red Tape and Other Regulatory Developments

7.8 Future Growth Strategies for CROs

7.8.1 Strategic Partnering for Long Term Revenue Growth

7.8.1.1 Sharing Risk Between Pharma and CROs

7.8.2 What Strategies Are Used for Selecting a CRO?

7.8.2.1 Small Pharmaceutical Companies and CROs

7.8.3 CRO Consolidation is Decreasing the Number of Mid-Sized Market Players

7.8.4 CROs Can Specialise to Grow

7.8.4.1 Orphan Diseases Are an Opportunity for Specialisation

7.9 The Future of Clinical Trials and CROs

7.9.1 New Trial Designs

7.9.1.1 Optimising Clinical Trials for Efficient Drug Development

7.9.2 Clinical Trial Globalisation

7.9.2.1 Consequences of Increased Outsourcing to Emerging Markets

7.9.3 Clinical Trials Have Become Increasingly Complex

7.10 Biomarkers Are Useful Tools for Accelerating Drug Development

8. Leading CROs in the Clinical Trials Services Industry in 2013

8.1 The Pharma Clinical Trial Services Market by Company 2011-20128.2 Quintiles: The Largest Player in the Pharma Clinical Trial Services Market8.2.1 Embracing Technology for New Service Offerings8.2.2 Expanding in Developed and Emerging Markets8.2.3 Will Quintiles Remain the Market Leader to 2023?8.3 Covance Is a Market Leader in Early Phase Services8.3.1 Covance Reorganises its Early Phase Sites8.3.2 Strong Late Phase Revenue Growth 2007-20118.3.3 How Will Covance Extend its Services Beyond 2012?8.4 PPD8.4.1 PPD: Another Global CRO to be Taken Private8.4.2 Investing in Technology for Growth8.4.3 PPD: Outlook 2013-20238.5 Parexel International8.5.1 Parexel is Targeting Growth in Asia8.5.2 Strong Growth for Clinical Trial Services 2010-20128.5.3 New Areas of Specialisation for Parexel8.6 ICON8.6.1 Multiple Acquisitions Have Increased ICON's Service Range8.6.1.1 Expanding Operations in China8.6.2 ICON: Recent Financial Performance and Outlook 2013-20238.7 INC Research8.7.1 From Mid-Sized to Large CRO: INC Acquires Kendle8.7.2 INC Adds New Technological Capabilities8.8 inVentiv Health8.8.1 Three Acquisitions Move inVentiv Closer to the Big Players8.8.2 Clinical Trial Service Revenue Growth 2011 and Beyond8.9 PRA International8.9.1 New Site Openings in Emerging Markets 2011-20128.9.2 Future Directions for PRA International8.10 CMIC: Japan's Largest CRO8.10.1 Increasing Asian Regional Reach8.10.2 CMIC Recent and Future Performance Analysis: An Asian Specialist8.11 Chiltern International8.11.1 Expanding into New Emerging Markets with Offices in Israel andTaiwan8.11.2 Chiltern International: Opportunities for Growth 2013-20238.12 There Are Many Other CROs in the Market in 20128.12.1 Charles River Laboratories Is an Expert in Pre-Clinical Services8.12.2 Clinipace Worldwide Is a Digital CRO8.12.2.1 Rapidly Expanding Through Acquisitions8.12.2.2 Clinipace Offers Many Technology Solutions8.12.3 ReSearch Pharmaceutical Services (RPS)8.12.4 Theorem Clinical Research8.12.4.1 An Established Presence in China8.12.5 WuXi PharmaTech8.12.5.1 WuXi is New to the Clinical Trial Services Market8.13 Leading Company Analysis8.13.1 Emerging Market Entry and Expansion8.13.2 How Are Global CROs Using Technology?8.13.3 How Are Leading Players Seeking to Differentiate Themselves?8.13.4 Medium-Sized Players Growing Larger Through Multiple Acquisitions8.13.5 Large CROs and Strategic Partnerships with Big Pharma

9. Research Interviews

9.1 Jodi Andrews , CEO, ProTrials Research

9.1.1 ProTrials Research

9.1.2 The Importance of the European Market

9.1.3 Expansion to Meet Demand

9.1.4 The Role of Small and Medium-Sized CROs in the Market

9.1.5 Technological Developments to Benefit Clinical Trials 2013-2023

9.1.6 Trends Affecting Clinical Trial Outsourcing 2013-2023

9.2 Dr Vladimir Bogin , President and CEO, Cromos Pharma

9.2.1 Cromos Pharma

9.2.2 The Advantages of Regional Specialisation

9.2.3 Considerations for Conducting Trials in the CEE Region

9.2.4 Future Growth Opportunities in the CEE Region

9.2.5 Challenges for Conducting Trials in the CEE Region

10. Conclusions from Our Study

10.1 The State of the Clinical Trial Services Market10.1.1 A Market Dominated by the Developed Countries10.2 Strong Growth for the Overall Market 2013-202310.3 Which CROs Can Take Best Advantage of Market Growth in the Next 10 Years?10.3.1 The Role of Technology in the Future of Clinical Trial Services10.3.2 How Can CROs Specialise to Remain Competitive?

List of Tables Table 1.1 Currency Exchange Rates, 2011

Table 2.1 Founding Members of the ICH

Table 2.2 Types of Adaptive Trial Design

Table 3.1 Breakdown of Pharma Clinical Spending by Phase

Table 3.2 Pharma Clinical Trial Services Market, 2008-2011

Table 3.3 Pharma Clinical Trial Services Market by Sector, 2011

Table 3.4 CRO Clinical Trial Services Revenue by Customer Type, 2011

Table 3.5 Pharma Clinical Trial Services Market: Overall Market and Revenue Forecasts by Sector, 2011-2023

Table 3.6 Clinical Trial Services Submarket Shares, 2011-2023

Table 3.7 Early Phase Clinical Trial Services Submarket Forecast, 2011-2023

Table 3.8 Late Phase Clinical Trial Services Submarket Forecast, 2011-2023

Table 4.1 World Pharma Clinical Trial Services Market by Region, 2011

Table 4.2 Pharma Clinical Trial Services Market: Revenue Forecasts by Country, 2011-2023

Table 4.3 Pharma Clinical Trial Services: Market Shares by Country, 2011-2023

Table 4.4 US Clinical Trial Services Market Forecast, 2011-2023

Table 4.5 Western European Clinical Trial Services Market by Country, 2011

Table 4.6 Western European Clinical Trial Services Market: Revenue Forecasts by Country, 2011-2023

Table 4.7 German Clinical Trial Services Market Forecast, 2011-2023

Table 4.8 French Clinical Trial Services Market Forecast, 2011-2023

Table 4.9 UK Clinical Trial Services Market Forecast, 2011-2023

Table 4.10 Italian Clinical Trial Services Market Forecast, 2011-2023

Table 4.11 Spanish Clinical Trial Services Market Forecast, 2011-2023

Table 4.12 Japanese Clinical Trial Services Market Forecast, 2011-2023

Table 5.1 Leading Emerging Markets for Pharma Clinical Trial Services, 2011

Table 5.2 Population Statistics in BRIC Nations, 2012

Table 5.3 Relative Competence in English in Emerging Markets, 2012

Table 5.4 Pharma Clinical Trial Services Market: Revenue Forecasts in Emerging Markets, 2011-2023

Table 5.5 Indian Clinical Trial Services Market Forecast, 2011-2023

Table 5.6 Chinese Clinical Trial Services Market Forecast, 2011-2023

Table 5.7 South Korean Clinical Trial Services Market Forecast, 2011-2023

Table 5.8 Russian Clinical Trial Services Market Forecast, 2011-2023

Table 5.9 CEE Clinical Trial Services Market Forecast, 2011-2023

Table 5.10 Brazilian Clinical Trial Services Market Forecast, 2011-2023

Table 6.1 Global Clinical Trials by Therapeutic Area, 2012

Table 6.2 Leading Therapeutic Areas for Clinical Trial Services, 2011

Table 6.3 Clinical Pipelines for Leading Therapeutic Areas, 2010-2012

Table 6.4 Pharma Clinical Trial Services Market: Revenue Forecasts for Leading Therapeutic Areas, 2011-2023

Table 6.5 Leading CROs Specialising in Biomarker Services, 2012

Table 6.6 Cancer Clinical Trial Services Submarket: Drivers and Restraints, 2011-2023

Table 6.7 Cancer Clinical Trial Services Submarket Forecast, 2011-2023

Table 6.8 Late-Stage Pipeline Failures in Alzheimer's Disease, 2009-2012

Table 6.9 CNS Disease Clinical Trial Services Submarket: Drivers and Restraints, 2011-2023

Table 6.10 CNS Disease Clinical Trial Services Submarket Forecast, 2011-2023

Table 6.11 Cardiovascular Disease Clinical Trial Services Submarket Forecast, 2011-2023

Table 6.12 Cardiovascular Disease Clinical Trial Services Submarket: Drivers and Restraints, 2011-2023

Table 6.13 Chronic Hepatitis B & C: Global Prevalence by Region, 2012

Table 6.14 Infectious Disease Clinical Trial Services Submarket Forecast, 2011-2023

Table 6.15 Infectious Disease Clinical Trial Services Submarket: Drivers and Restraints, 2011-2023

Table 6.16 Metabolic Disease Clinical Trial Services Submarket Forecast, 2011-2023

Table 6.17 Metabolic Disease Clinical Trial Services Submarket: Drivers and Restraints, 2011-2023

Table 6.18 Selected Imaging Specialist CROs, 2012

Table 7.1 Pharma Clinical Trial Services Market: Strengths and Weaknesses, 2012

Table 7.2 Pharma Clinical Trial Services Market: Opportunities and Threats, 2013-2023

Table 7.3 Biosimilar Guidance Drafted Using Elements of EU Guidelines, 2008-2012

Table 7.4 Pharma Clinical Trial Services Market: STEP Analysis, 2013-2023

Table 7.5 Selected Online Communities to Aid Patient Recruitment and Trial Involvement, 2012

Table 7.6 Selected CROs Investing in Technology, 2011-2012

Table 7.7 Selected Sources of Biomarkers and Relevant Research Technology, 2012

Table 7.8 Growth in the Biomarker Services Market, 2011, 2016 & 2022

Table 8.1 World CRO Market by Company, 2011

Table 8.2 Covance: Revenue by Sector, 2007-2011

Table 8.3 Covance: Revenue by Sector, Q1-Q3 2011-2012

Table 8.4 PPD: Revenue by Sector, Q1-Q2 2010-2011

Table 8.5 Parexel International: Revenue by Sector, 2010-2012

Table 8.6 Parexel International: Revenue by Region, 2012

Table 8.7 ICON: Revenue by Sector, 2010-2011

Table 8.8 ICON: Revenue by Region, 2010-2011

Table 8.9 Kendle: Revenue by Sector, 2009-2010

Table 8.10 inVentiv Health: Revenue by Sector, Q2 2010 & Q2 2011

Table 8.11 CMIC: CRO Revenue, 2008-2012

Table 8.12 Chiltern International: Therapeutic Experience

Table 8.13 Chiltern International: Revenue, 2008-2010

Table 8.14 Selected Strategic Partnerships Signed, 2011-2012

Table 10.1 Pharma Clinical Trial Services Market by Sector, 2011, 2017 & 2023

List of Figures Figure 2.1 A Brief History of Clinical Trials

Figure 3.1 Breakdown of Pharma Clinical Spending by Phase

Figure 3.2 Pharma Clinical Trial Services Market, 2008-2011

Figure 3.3 Pharma Clinical Trial Services Market by Sector, 2011

Figure 3.4 CRO Clinical Trial Services Revenue by Customer Type, 2011

Figure 3.5 Clinical Trial Services Market: Drivers and Restraints, 2013-2023

Figure 3.6 Pharma Clinical Trial Services Market Forecast, 2011-2023

Figure 3.7 Pharma Clinical Trial Services Market by Sector, 2017

Figure 3.8 Pharma Clinical Trial Services Market by Sector, 2023

Figure 3.9 Early Phase Clinical Trial Services Submarket Forecast, 2011-2023

Figure 3.10 Early Phase Trial Services Submarket: Drivers and Restraints, 2013-2023

Figure 3.11 Late Phase Clinical Trial Services Submarket Forecast, 2011-2023

Figure 3.12 Late Phase Trial Services Submarket: Drivers and Restraints, 2013-2023

Figure 4.1 World Pharma Clinical Trial Services Market by Region, 2011

Figure 4.2 World Pharma Clinical Trial Services Market by Region, 2017

Figure 4.3 World Pharma Clinical Trial Services Market by Region, 2023

Figure 4.4 US Clinical Trial Services Market Forecast, 2011-2023

Figure 4.5 Western European Clinical Trial Services Market by Country, 2011

Figure 4.6 Western European Clinical Trial Services Market Forecast, 2011-2023

Figure 4.7 German Clinical Trial Services Market Forecast, 2011-2023

Figure 4.8 French Clinical Trial Services Market Forecast, 2011-2023

Figure 4.9 UK Clinical Trial Services Market Forecast, 2011-2023

Figure 4.10 Italian Clinical Trial Services Market Forecast, 2011-2023

Figure 4.11 Spanish Clinical Trial Services Market Forecast, 2011-2023

Figure 4.12 Japanese Clinical Trial Services Market Forecast, 2011-2023

Figure 5.1 Leading Emerging Markets for Pharma Clinical Trial Services, 2011

Figure 5.2 Cost Savings Available for Clinical Trials in Emerging Markets, 2012

Figure 5.3 Relative Competence in English in Emerging Markets, 2012

Figure 5.4 Pharma Clinical Trial Services: Emerging Market Forecasts, 2011-2023

Figure 5.5 Indian Clinical Trial Services Market Forecast, 2011-2023

Figure 5.6 Chinese Clinical Trial Services Market Forecast, 2011-2023

Figure 5.7 South Korean Clinical Trial Services Market Forecast, 2011-2023

Figure 5.8 Russian Clinical Trial Services Market Forecast, 2011-2023

Figure 5.9 CEE Clinical Trial Services Market Forecast, 2011-2023

Figure 5.10 Brazilian Clinical Trial Services Market Forecast, 2011-2023

Figure 6.1 Global Clinical Trials by Therapeutic Area, 2012

Figure 6.2 Leading Therapeutic Areas for Clinical Trial Services, 2011

Figure 6.3 Pharma Clinical Trial Services Market: Revenue Forecasts for Leading Therapeutic Areas, 2011, 2017 & 2023

Figure 6.4 Cancer Clinical Trial Services Submarket Forecast, 2011-2023

Figure 6.5 CNS Disease Clinical Trial Services Submarket Forecast, 2011-2023

Figure 6.6 Cardiovascular Disease Clinical Trial Services Submarket Forecast, 2011-2023

Figure 6.7 Chronic Hepatitis B & C: Global Prevalence by Region, 2012

Figure 6.8 Infectious Disease Clinical Trial Services Submarket Forecast, 2011-2023

Figure 6.9 Metabolic Disease Clinical Trial Services Submarket Forecast, 2011-2023

Figure 7.1 The 3+3 Staging Trial Design

Figure 7.2 Growth in the Biomarker Services Market, 2011, 2016 & 2022

Figure 8.1 World CRO Market by Company, 2011

Figure 8.2 Quintiles: Risk-Sharing Partnerships, 2002-2011

Figure 8.3 Covance: Revenue by Sector, 2007-2011

Figure 8.4 Covance: Revenue by Sector, Q1-Q3 2011-2012

Figure 8.5 PPD: Revenue by Sector, Q1-Q2 2010-2011

Figure 8.6 Parexel International: Revenue by Sector, 2010-2012

Figure 8.7 Parexel International: Revenue by Region, 2012

Figure 8.8 ICON: Revenue by Sector, 2010-2011

Figure 8.9 ICON: Revenue by Region, 2011

Figure 8.10 Kendle: Net Service Revenue by Sector, 2010

Figure 8.11 inVentiv Health: Revenue by Sector, Q2 2010 & Q2 2011

Figure 8.12 CMIC: CRO Revenue, 2008-2012

Figure 8.13 Chiltern International's Clinical Trials: Therapeutic Experience

Figure 8.14 Chiltern International: Revenue, 2008-2010

Figure 10.1 Pharma Clinical Trial Services Market by Sector, 2011, 2017 & 2023

Companies Listed 3C Alliance

Agência Nacional de Vigilância Sanitária (ANVISA) [Brazil]

Agility Clinical

Allscripts

Amgen

Aptuit

ASAN Medical Center

Associação Brasileira de CROs (Abracro)

Association for the Accreditation of Human Research Protection Programs (AAHRPP)

Association of Clinical Trial Organisations (ACTO) [Russia]

Astellas Pharma

Avista Capital Partners

Bayer

BeijingWits Medical Consulting (part of ICON)

Berry Consultants

BioClinica

BioDuro (part of PPD)

BioDuro Biologics

BioTrak

BML

Boehringer Ingelheim

Bristol- Myers Squibb

Caprion Proteomics

Catalent

Center for Biologics Evaluation and Research (CBER) [US]

CenterWatch

Central Drugs Standard Control Organization (CDSCO) [India]

Charles River Laboratories

Chinese Ministry of Commerce

Clinical Trial Support

Clinigene International

Clinipace Worldwide

ClinStar

CMIC

CMIC (Beijing) Co

CNS Healthcare

CNS Vital Signs

Cogtest (part of The Cognition Group)

Corex Pharmaceutical

Council for International Organizations of Medical Sciences (CIOMS)

Cromos Pharma

Czura Thornton

Dako (part of Agilent Technologies)

Department of Health [UK]

Drug Controller General of India (DCGI)

Eisai

Ekam Imaging

Eli Lilly

European Commission

European Federation of Pharmaceutical Industries and Associations (EFPIA)

European Medicines Agency (EMA)

European Parliament

Firecrest Clinical (part of ICON)

Food and Drug Administration (US FDA)

GCP ClinPlus

GE Healthcare

Genstar Capital

Global CNS Research

Global Research Services (GRS)

GSK

Hellman & Friedman

i3 Research (part of inVentiv Health)

ICON

INC Research

Infociencia (part of RPS)

Innovative Medicines Initiative (IMI)

Inspire

Institute for Medical Research Management and Biometrics (IMEREM, part of RPS)

Integrium

International Cancer Genome Consortium

International Conference of Harmonisation (ICH)

inVentiv Health

J&J

Japan Pharmaceutical Manufacturers Association (JPMA)

Java Clinical

Julphar

Kendle (part of INC Research)

Kforce

Kforce Clinical Research (KCR, part of inVentiv Health)

Kinship Technologies (part of PRA)

Korea Drug Development Fund (KDDF)

Korea Food and Drug Administration (KFDA)

Korea National Enterprise for Clinical Trials (KoNECT)

Kun Tuo (part of Quintiles)

LSK Global

MAB Discovery

Malaysian Biotechnology Corporation

Maximax Pharmaceutical Research

MDS Pharma Services (part of INC Research)

MedAvante

Medelis

Medicines and Healthcare products Regulatory Agency (MHRA) [UK]

Medidata Solutions

Medipal Holdings

Medivation

Merck & Co.

Merck KGaA

Metabolon

MetricStream

Ministry of Health, Labor and Welfare (MHLW, Japan)

Molecular Neuroimaging

Myriad Genetics

National Cancer Institute (NCI) [US]

National Taiwan University Hospital (NTUH)

Nautic Partners

Neuroimage

NextGen Sciences

Nexus Oncology

NHS Research Scotland (NRS)

OCT

Omnicare

Ontario Teachers' Pension Plan

Oxford Cancer Biomarkers

Oxford Gene Technology (OGT)

Oxford Outcomes (part of ICON)

Pacific Biomarkers

Paragon Biomedical (part of Clinipace Worldwide)

Paramax International (part of RPS)

Parexel International

Perceptive Informatics (part of Parexel)

PFC Pharma Focus (part of Clinipace Worldwide)

Pfizer

Pharmaceutical Research and Manufacturers of America (PhRMA)

Pharmaceuticals and Medical Devices Agency (PMDA) [Japan]

PharmaNet Development Group (part of inVentiv Health)

PPD

PRA International

Prana Biotechnology

PriceSpective (part of ICON)

Prodia Clinical Laboratory

Proteome Sciences

ProTrials Research

Psychmed (part of The Cognition Group)

QED Clinical Services

Quintiles

Regulus Pharmaceutical Consulting (part of Clinipace Worldwide)

ReSearch Pharmaceutical Services (RPS)

Rules Based Medicine (now Myriad RBM, part of Myriad Genetics)

Samsung

SAS

Shanghai Clinical Research Center

ShangPharma

Shire

State Food and Drug Administration (SFDA) [China]

Sugi Medical Co (part of CMIC)

Taijitu Biologics

Tessella

The Carlyle Group

The Cognition Group

Theorem Clinical Research

Theradex Systems

Therapeutic Goods Administration (TGA) [Australia]

Therapharm Recherches (part of RPS)

Thomas H. Lee Partners

Tigermed Consulting

Timaq Medical Imaging (part of ICON)

Trident Clinical Research (part of INC Research)

UCB

Veeda Clinical Research

Vigiun (part of Chiltern International)

VirtualScopics

Warburg Pincus

West Coast Clinical Trials (WCCT)

World Health Organization (WHO)

Worldwide Clinical Research

WuXi AppTec

WuXi PharmaTech

To order this report:Drug_Discovery_and_Development Industry: Pharma Clinical Trial Services: World Market 2013-2023

Contact Clare: clare@reportlinker.com
US:(339) 368 6001
Intl:+1 339 368 6001

 


'/>"/>
SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved


Related medicine technology :

1. Imprimis Pharmaceuticals Out Licenses Its Proprietary IP to resolutionMD for Cosmeceutical Products
2. Auxilium Pharmaceuticals, Inc. to Present at the Cowen and Company 33rd Annual Healthcare Conference
3. Arena Pharmaceuticals Provides Corporate Update and Reviews Fourth Quarter and Full Year 2012 Financial Results
4. PDL BioPharma Announces Fourth Quarter and Full Year 2012 Financial Results
5. AVANIR Pharmaceuticals To paticipate in two conferences in March
6. Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss Fourth Quarter And Full Year 2012 Financial Results On March 7, 2013
7. Adamis Pharmaceuticals Prevails in License Dispute Litigation
8. Cumberland Pharmaceuticals Reports 2012 Annual Financial Results
9. On-Demand Reports on Partnering Terms in Healthcare & Pharma Sectors: New Market Research at ReportsnReports.com
10. DelMar Pharmaceuticals Announces Appointment of John K. Bell to Board of Directors
11. Spring Bank Pharmaceuticals Closes $10.5 million Series A Financing to fund Phase I Clinical Trials in HCV-infected Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... F ast ... at the point of ... technical and medical information products and services, has launched a ClinicalKey ... information via a mobile device. Elsevier designed the mobile app to allow ... app is available in Android and iOS formats ...
(Date:2/11/2016)... Fla. , Feb. 11, 2016 ... ) company providing high-quality specialty pharmacy care for ... announced today it has achieved full Specialty Pharmacy ... accrediting organization dedicated to promoting health care quality ... --> --> The URAC accreditation ...
(Date:2/11/2016)... "team investment" by Bruce Montgomery , one of this area,s most prominent biotech executives, and ... Kawas , PhD. Photo - http://photos.prnewswire.com/prnh/20160211/332242 ... ... ... Kawas said the round was intended to be an $8 million raise ...
Breaking Medicine Technology:
(Date:2/11/2016)... AR (PRWEB) , ... February 11, 2016 , ... Dickinson ... their community by announcing a new fundraiser in support of a local boy named ... hopes the campaign will bring awareness to, and rally support for, all local families ...
(Date:2/11/2016)... ... February 11, 2016 , ... From March 4 through 6, ... Annual Meeting at the Walter E. Washington Convention Center in Washington, D.C. , ... condition of hyperhidrosis (excessive sweating) and its treatment options. Specifically, the company will ...
(Date:2/11/2016)... , ... February 11, 2016 , ... The book, “Computers ... IT services, what questions to ask your IT consultant before signing a contract and ... your computer network. , “With companies relying heavily on e-mail and technology, it’s more ...
(Date:2/10/2016)... ... February 10, 2016 , ... The 9th annual meeting ... Congress (WMIC), will be held in New York City, NY on September 7 ... The congress will highlight and emphasize how imaging reveals a greater understanding of ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... company offering education, research and medical media, has launched Contagion® , ... infectious diseases. , As the all-inclusive resource for infectious disease information, Contagion ...
Breaking Medicine News(10 mins):